Valuation : TAUNS Laboratories,Inc.

Market Cap 53.78B 345M 297M 279M 255M 477M 32.54B 478M 3.3B 1.28B 16.69B 1.29B 1.27B P/E 2026 *
10.1x
P/E 2027 * 14.9x
Enterprise Value 61.77B 396M 341M 320M 293M 548M 37.37B 549M 3.79B 1.47B 19.17B 1.49B 1.45B EV / Sales 2026
-
EV / Sales 2027 * 3.25x
Free-Float
31.24%
Yield 2026 *
7%
Yield 2027 * 5.56%
1 day+0.60%
1 week-0.98%
Current month-0.40%
1 month+8.62%
3 months+2.86%
6 months-5.97%
Current year-0.98%
1 week 500
Extreme 500
509
1 month 466
Extreme 466
512
Current year 463
Extreme 463
568
1 year 463
Extreme 463
581
3 years 401
Extreme 401
733
5 years 401
Extreme 401
733
10 years 401
Extreme 401
733
Manager TitleAgeSince
Chief Executive Officer 51 30/04/2014
Director of Finance/CFO 67 31/10/2018
Corporate Officer/Principal 39 30/06/2022
Director TitleAgeSince
Director/Board Member 51 30/04/2014
Director/Board Member 67 31/08/2020
Director/Board Member 53 31/03/2016
Change 5-day change 1-year change 3-year change Capi.($)
+0.60%-0.98%-11.89% - 345M
+0.23%-0.06%+168.44%+357.12% 21.66B
-2.24%-1.33%-37.24%-20.96% 10.16B
-0.90%+1.80%+348.78%+19.38% 8.16B
-0.99%-2.18%-28.06% - 7.08B
-0.01%+0.20%+84.42%+52.87% 6.59B
+2.34%-1.27%-20.74%-15.41% 6.03B
-1.82%-1.64%-8.48%-20.67% 4.33B
-0.62%-0.38%+74.99%+85.77% 4.22B
+1.82%-0.27%-18.67%-28.71% 2.81B
Average -0.16%-0.48%+55.16%+53.67% 7.14B
Weighted average by Cap. -0.33%-0.26%+92.07%+127.08%

Financials

2026 2027 *
Net sales 14.76B 94.56M 81.36M 76.55M 69.93M 131M 8.93B 131M 905M 351M 4.58B 355M 347M 19.25B 123M 106M 99.88M 91.24M 171M 11.65B 171M 1.18B 458M 5.98B 463M 453M
Net income 5.2B 33.33M 28.68M 26.98M 24.65M 46.11M 3.15B 46.24M 319M 124M 1.61B 125M 122M 3.59B 23.02M 19.81M 18.64M 17.03M 31.85M 2.17B 31.94M 220M 85.47M 1.12B 86.45M 84.56M
Net Debt 7.99B 51.22M 44.08M 41.47M 37.88M 70.87M 4.84B 71.06M 490M 190M 2.48B 192M 188M 8.75B 56.1M 48.27M 45.42M 41.49M 77.61M 5.3B 77.82M 537M 208M 2.72B 211M 206M
Logo TAUNS Laboratories,Inc.
Tauns Laboratories Inc is a Japan-based company engaged in the business of developing, manufacturing and marketing in vitro diagnostic products and research reagents. The Company operates its business in the in vitro diagnostic products business segment. The Company’s main product is antigen test kit that uses immunochromatography to enable rapid diagnosis at the patient's side without the need for special equipment. The products include ImunoAce Flu, ImunoAce SARSCoV-2 II, ImunoAce SARSCoV-2 Saliva, ImunoAce SARSCoV-2/Flu, ImunoAce Adeno, ImunoAce Strep A Neo, ImunoAce hMPV, ImunoAce Mycopiasma, ImunoAce RSV Neo and ImunoAce Noro.
Employees
218
Date Price Change Volume
04/09/26 JP¥504.00 +0.60% 174,500
03/09/26 JP¥501.00 -0.99% 198,900
02/09/26 JP¥506.00 -0.59% 152,600
01/09/26 JP¥509.00 +0.59% 152,700
31/08/26 JP¥506.00 -0.59% 138,700
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
2
Last Close Price
504.00JPY
Average target price
420.00JPY
Spread / Average Target
-16.67%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 197A Stock